Cell and gene therapy manufacturing services market seen doubling by 2030

The Business Research Company says the global cell and gene therapy manufacturing services market will rise from $9.44 billion in 2025 to $21.05 billion by 2030, led by demand for outsourced production and larger-scale advanced therapy capacity. North America led in 2025, while Asia-Pacific is projected to be the fastest-growing region.

Why it matters: - The market sits at the center of a broader push to commercialize cell and gene therapies for cancer, genetic disorders and tissue injuries. - Faster manufacturing scale-up could help move more therapies from clinical trials into patient use. - Demand is growing for specialized bioprocessing services, quality control and GMP-compliant production capacity.

What happened: - The Business Research Company published its Cell and Gene Therapy Manufacturing Services Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the market will grow from $9.44 billion in 2025 to $11.08 billion in 2026. - The report projects the market will reach $21.05 billion by 2030. - The forecast implies a 17.4% compound annual growth rate from 2025 through 2030. - The report is available as a free sample and as a full report, both linked by the company.

The details: - The report ties recent growth to more cell and gene therapy candidates entering clinical trials. - Early adoption of outsourced manufacturing has also supported demand. - Broader academic translational research has added to market growth. - Limited in-house manufacturing capacity has pushed developers toward external service providers. - The report cites a rising need for specialized bioprocessing services as another driver. - Looking ahead, the company points to stronger commercialization of cell and gene therapies, more demand for large-scale manufacturing, expansion of personalized medicine pipelines, clearer regulation and heavier investment in production infrastructure. - The report highlights emerging trends including GMP-compliant manufacturing facilities, automated cell processing, scalable viral vector production, advanced quality control and manufacturing standardization. - The report defines these services as the manufacturing and quality control processes used to produce gene and cell therapy products. - The service set includes GMP-compliant ancillary reagents, flow cytometry, immunoassays and gene engineering services. - The report says these services support treatments for degenerative diseases, tissue injuries and genetic disorders. - The company says the report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis.

Between the lines: - The market's growth rate suggests demand is outpacing the current manufacturing base. - That points to a continued outsourcing model, at least until more companies build internal capacity or partner for scale. - The emphasis on automation, viral vector production and quality control suggests the bottleneck is moving from research toward industrial execution. - The report's regional split also shows where capacity and commercial activity are likely to concentrate next. - The American Cancer Society expects about 316,950 new invasive breast cancer cases in women and 2,800 in men in the U.S. in 2025, underscoring the disease burden behind therapy development.

What's next: - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Companies and investors are likely to focus on GMP capacity, scalable vector manufacturing and standardized production systems as the market expands. - The Business Research Company says it is offering updated market graphics, tables and forecasting tools in its 2026 report set.

The bottom line: - Cell and gene therapy manufacturing services are moving from a niche support function to a core part of the advanced therapy supply chain.